Responses
Therapeutics
Randomised controlled trial
Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 17 January 2012
- Published on: 17 January 2012Perplexity.Show More
Dear Editor,
As a practicing clinician, who reads Evidence Based Medicine to keep up to date with significant progress in medicine, I cannot help feeling perplexed about the review of Ambrosy and Gheorghiade on the article by Zannad et al (Eplerenone in patients withsystolic heart failure and mild symptoms, NEJM 2011; 364 : 11-21). Throughout their commentary, the reviewers fail to mention that the main conclusion...
Conflict of Interest:
None declared.